Pfizer/BioNTech’s Comirnaty (tozinameran) is forecasted to reach $24.8bn by 2021
Pfizer/BioNTech’s Comirnaty (tozinameran) is conjecture to have top sales of $24.8bn by 2021, which is just its second year available.
Read morePfizer/BioNTech’s Comirnaty (tozinameran) is conjecture to have top sales of $24.8bn by 2021, which is just its second year available.
Read more